REFERENCES
- Wise R. The clinical relevance of protein binding and tis-sue concentrations in antimicrobial therapy. Clin Pharmacokinet 1986; 11: 470–482.
- Nath SK, Foster G, Mandell LA, Rotstein C. Antimicrobial activity of ceftriaxone versus cefotaxime: nega-tive effect of serum albumin binding of ceftriaxone. J Antimicrob Chemother 1994; 33: 1239–1243.
- Patel G, Chau NP, Pangon B et al. Single daily dosing of antibiotics: importance of in vitro killing rate, serum half-life, and protein binding. Antimicrob Agents Chemother 1991; 34: 2085-2090.
- Moine P, Vallee E, Dupuis EA et al. In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoni-ae in a mouse pneumonia model. Antimicrob Agents Chemother 1994; 38: 1953–1958.
- Mays B, Short L, Hershman MJ, Cheadle WG. Relevance of protein binding to cephalosporin antimicrobial activity in vivo. Chemotherapy 1990; 36: 254–258.
- Boswell FJ, Ashby JP, Andrews JM, Wise R. 2002. Effect of protein binding on the in vitro activity and pharma-codynamics of faropenem. J Antimicrob Chemother 2002; 50: 525–532.
- Jones RN, Barry AL. Antimicrobial activity of ceftriax-one, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylceftoaxime in the presence of human serum. Antimicrob Agents Chemother 1987; 31: 818–820.
- Leggett JE, Craig WA. Enhancing effect of serum ultra-filtrate on the activity of cephalosporins against Gram-negative bacilli. Antimicrob Agents Chemother 1989; 33: 35–40.
- Perl TM, Pfaller A, Houston A, Wenzel RP. Effect of serum on the in vitro activities of 11 broad-spectrum antibi-otics. Antimicrob Agents Chemother 1990; 34: 2234-2239.
- Bakker-Woudenberg IAJM, Berg JCVD, Vree TB, Baars AM. Relevance of serum protein binding of cefoxitin and cefazolin to their activities against Klebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother 1985; 28: 654–659.
- Barry AL, Jones RN, and Packer RR. Antistaphylococcal activity of ceforanide and cefonicid in the presence of human serum. Antimicrob Agents Chemother 1986; 29: 147–149.
- Palmer SM, Kang SL, Cappelletty DM, Rybak MJ. Bactericidal killing antibiotics of cefepime, ceftazidime, cefo-taxime and ceftriaxone against Staphylococcus aureus and 13-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model. Antimicrob Agents Chemother 1995; 39: 1764–1771.
- Schafer-Korting M, Korting HC, Amann F, Peuser R, Lukacs A. Influence of albumin on itraconazole and ketocona-zole antifungal activity: results of a dynamic in vitro study. Antimicrob Agents Chemother 1991; 35: 2053–2056.
- National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacte-ria that grow aerobically, 3rd ed. 1993. Approved standard M7-A3. Villanova, PA.
- Li RC. Simultaneous pharmacodynamic analysis of the lag and bactericidal phases exhibited by I3-lactams against Escherichia coli. Antimicrob Agents Chemother 1996; 140: 2306–2310.
- Li RC, Zhu M, Schentag JJ. Achieving an optimal out-come in the treatment of infections: the role of clinical phar-macokinetics and pharmacodynamics for antimicrobials. Clin Pharmacokinet 1999; 37: 1–16.
- Szybaloki W. Microbial selection: I. gradient plate tech-nique for study of bacterial resistance. Science 1952; 116: 46–48.
- Odenholt I, Holm SE, Cars O. Effect of antibiotic pro-tein binding on the killing rate of Staphylococcus aureus and on the paradoxical phenomenon. Chemotherapy 1987; 33: 331–339.
- Hunt DE, Sandham HJ. Improved agar gradient plate technique. Appl Microbiol 1969; 17: 329–330.